NOV 12, 2015 9:00 AM PST

Use of a CD200R Inhibitor to Overcome Central Nervous System Tumor Induced Immunosuppression

Speaker
  • Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Minnesota
    BIOGRAPHY

Abstract

Cancer immunotherapy has demonstrated promising results. However, to date, researchers have failed to overcome the complex interplay between the immune system and the immune suppressive tumor microenvironment. Progression to a productive immune response involves passing a number of immunological checkpoints, which act as barriers for productive immunotherapies. To overcome this limitation, the FDA-approved monoclonal antibodies, ipilimumab, pembrolizumab and nivolumab, respectively, which inhibits the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD1) and programmed death 1 ligand (PD-L1) checkpoints. Both anti-CTLA4 and anti-PD1 act directly on T cells. In contrast, a third immunological checkpoint act directly on antigen presenting cells inducing T-cell tolerance. This checkpoint arises from the engagement of CD200 and it’s receptor (CD200R). CD200 is expressed in a variety of human tumors including melanoma and glioblastomas. However, it is the soluble form of CD200 that correlates with poor patient outcome. We reported that CD200 concentration significantly increased in the sera of glioma patients as their tumors progressed, which correlated with increased lineage negative myeloid derived suppressor cell (MDSC) population. We developed an inhibitor of the CD200 (CD200R antagonist) that acts directly on the CD200R on antigen presenting cells overpowering the suppressive properties of CD200. Our CD200R antagonist inhibits myeloid derived suppressor cell expansion, enhances cytokine and chemokine production significantly enhancing survival in both glioma and breast carcinoma tumor models.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
NOV 12, 2015 9:00 AM PST

Use of a CD200R Inhibitor to Overcome Central Nervous System Tumor Induced Immunosuppression



Show Resources
Loading Comments...
Show Resources